COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: First national case series.

[1]  D. Centonze,et al.  Drugs Used in the Treatment of Multiple Sclerosis During COVID-19 Pandemic: A Critical Viewpoint , 2021, Current neuropharmacology.

[2]  A. Carrá,et al.  COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America , 2021, Multiple Sclerosis and Related Disorders.

[3]  Meral Mirza,et al.  Transient monocular visual impairment as an initial symptom of COVID-19 infection in an individual with multiple sclerosis receiving teriflunomide , 2021, Neurological Sciences.

[4]  M. Sahraian,et al.  COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review , 2021, Multiple Sclerosis and Related Disorders.

[5]  M. Sormani,et al.  Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis , 2021, Annals of neurology.

[6]  F. Journé,et al.  Prevalence and 6‐month recovery of olfactory dysfunction: a multicentre study of 1363 COVID‐19 patients , 2021, Journal of internal medicine.

[7]  V. Di Lazzaro,et al.  COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review , 2021, Multiple Sclerosis and Related Disorders.

[8]  M. Ghasemi-Kasman,et al.  Impact of disease‐modifying drugs on the severity of COVID‐19 infection in multiple sclerosis patients , 2020, Journal of medical virology.

[9]  M. Zaffaroni,et al.  Mild COVID‐19 infection in a group of teriflunomide‐treated patients with multiple sclerosis , 2020, Journal of Neurology.

[10]  A. Conte,et al.  The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia , 2020, Journal of Neuroimmunology.

[11]  M. Trojano,et al.  Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide , 2020, Journal of the Neurological Sciences.

[12]  C. Louapre,et al.  Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. , 2020, JAMA neurology.

[13]  M. Wattjes,et al.  Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse , 2020, Journal of Neurology.

[14]  M. Filippi,et al.  COVID-19 in teriflunomide-treated patients with multiple sclerosis , 2020, Journal of Neurology.

[15]  P. Kuppen,et al.  Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile , 2019, Cancer Immunology, Immunotherapy.